Additionally, the ICC 2022 has introduced a new disease category, MDS/AML, characterized by 10–19%blasts and the presence of high-risk mutations such as TP53, ASXL1, BCOR, EZH2, RUNX1, SF3B1, STAG2, U2AF1, or ZRSR2. This category acknowledges the overlapping features of MDS and AML in certain patients but does not currently extend to CMML, which remains classified separately despite potential molecular overlaps. Here, U2AF1 is linked to acute myeloid leukemia.